Yanjun Wang

Yanjun Wang

Auto-generated profile, based on publicly available information

Yanjun Wang

Department of Hepatobiliary and Pancreatic Surgery, the Second Affiliated Hospital, Fujian Medical University, Quanzhou, CHINA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Surgical Endoscopy
Verified
Journal Article
Open access
PDF file
YWYanjun Wang
Yanjun Wang
YHYoubao Huang
Youbao Huang
CSChunfeng Shi
Chunfeng Shi
LWLinpei Wang
Linpei Wang
Shengwei LiuShengwei Liu
Shengwei Liu
WWWei Wang
Wei Wang
Background: T-tube drainage after laparoscopic common bile duct exploration (LCBDE) has been demonstrated to be safe and effective for patients with acute cholangitis caused by common bile duct stones (CBDSs). The outcomes after LCBDE with primary closure in patients with CBDS-related acute cholangitis are unknown. The present study aimed to evaluate the efficacy and safety of LCBDE with primary closure for the management of acute cholangitis caused by CBDSs. Methods: Between June 2015 and June 2020, 368 consecutive patients with choledocholithiasis combined with cholecystolithiasis, who underwent laparoscopic cholecystectomy (LC) + LCBDE in our department, were retrospectively reviewed. A total of 193 patients with CBDS-related acute cholangitis underwent LC + LCBDE with primary closure of the CBD (PC group) and 62 patients underwent LC + LCBDE followed by T-tube placement (T-tube group). A total of 113 patients who did not have cholangitis were excluded. The clinical data were compared and analyzed. Results: There was no mortality in either group. No significant differences were noted in morbidity, bile leakage rate, retained CBD stones, or readmission rate within 30 days between the two groups. Compared with the T-tube group, the PC group avoided T-tube-related complications and had a shorter operative time (121.12 min vs. 143.37 min) and length of postoperative hospital stay (6.59 days vs. 8.81 days). Moreover, the hospital expenses in the PC group were significantly lower than those in the T-tube group ($4844.47 vs. $5717.22). No biliary stricture occurred during a median follow-up of 18 months in any patient. No significant difference between the two groups was observed in the rate of stone recurrence. Conclusions: LCBDE with primary closure is a safe and effective treatment for cholangitis caused by CBDSs. LCBDE with primary closure is not inferior to T-tube drainage for the management of CBDS-related acute cholangitis in suitable patients.

1 January 2021 in Forensic Science International
Verified
Journal Article
Closed access
XLXiao Li
Xiao Li
YYYi Ye
Yi Ye
YWYanjun Wang
Yanjun Wang
XDXinhua Dai
Xinhua Dai
SFShiyong Fang
Shiyong Fang
LLLinchuan Liao
Linchuan Liao

10 January 2023 in Cancer
Verified
Journal Article
Closed access
JZJiawei Zhang
Jiawei Zhang
QHQiming Huang
Qiming Huang
YYYi Yang
Yi Yang
JZJiahui Zhang
Jiahui Zhang
XFXueting Fang
Xueting Fang
YWYanjun Wang
Yanjun Wang

18 October 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
XLXin Luo
Xin Luo
RCRui-Zhi Chang
Rui-Zhi Chang
DKDong Kuang
Dong Kuang
MYMingming Yuan
Mingming Yuan
GLGan-Xun Li
Gan-Xun Li
ZDZeyang Ding
Zeyang Ding
Background: Advanced hepatocellular carcinoma (HCC) shows poor prognosis. Combined hepatic artery infusion chemotherapy (HAIC) and lenvatinib and PD-1 antibody therapy show promising effects in treating advanced HCC, and salvage hepatectomy further promotes the overall survival in patients who were successfully converted after combined therapy. However, salvage major hepatectomy is not always amenable due to insufficient future liver remnant volume (FLV).Case presentation: We report the case of a 59-year-old man with a huge HCC as well as multiple intrahepatic foci and portal vein tumor thrombosis at his right hemi-liver. Genomic and pathologic analyses of HCC tissue revealed a TMB-high, TPS, and CPS-high cancer, with mutated DNA damage repair gene FANCC. These results suggested that this patient may benefit from chemotherapy and immunotherapy. Thus, he received combined HAIC, lenvatinib, and PD-1 antibody treatment and showed a quick and durable response. After successful downstaging, this patient was evaluated as not suitable for salvage hepatectomy due to the low FLV. He then received simultaneous transcatheter arterial chemoembolization (TACE) and portal vein embolization (PVE). The FLV increased to meet the criteria of salvage hepatectomy. Finally, this patient underwent right hemi-hepatectomy without any severe perioperative complications. In addition, no tumor recurrence occurred during the 9-month follow-up period after surgery.Conclusion: Combined HAIC, lenvatinib, and PD-1 antibody therapy, followed by simultaneous TACE and PVE, is a safe and effective conversion therapy that promotes tumor necrosis and increase FLV in patients with advanced HCC.

24 July 2023 in Surgery
Verified
Journal Article
Closed access
JZJiahui Zhang
Jiahui Zhang
YWYanjun Wang
Yanjun Wang
TZTong Zhang
Tong Zhang
DXDongyao Xu
Dongyao Xu
CSChunfeng Shi
Chunfeng Shi
WWWei Wang
Wei Wang